[ad_1] USFDA Grants Tentative Approval, 180-Day Exclusivity to Granules’ Generic Amphetamine XR We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Cipla Partner Pharmathen Receives 9 USFDA Observations We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Biocon Biologics Eyes USD 75 Billion Oncology Market, Adds 3 New Biosimilar Drugs We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] USFDA Approves Agios Pharma’s Aqvesme for Alpha, Beta Thalassemia Anemia We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] After 40 Years, USFDA Approves Vanda Pharma’s Motion Sickness Drug Nereus We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok [ad_2] Source link
[ad_1] Sun Pharmaceutical Industries Ltd on Thursday said the US Food and Drug Administration (FDA) has classified its Baska manufacturing facility under Official Action Indicated (OAI) following a recent inspection, even as the company said supplies to the US market from the plant will continue. In an exchange filing, Sun Pharma said, “This is to…
[ad_1] Drug firm Wockhardt on Monday said the US health regulator has accepted the new drug application (NDA) status for its novel, first-in-class antibiotic Zaynich. The NDA was filed on September 30, 2025, and its acceptance marks a transformative moment – not only for Wockhardt, but also for the entire Indian pharmaceutical industry, the Mumbai-based…
[ad_1] Zydus Lifesciences Ltd on Friday said it has received final approval from the US health regulator for its generic version of Leuprolide Acetate injection used in palliative treatment of advanced prostatic cancer. The approval by the US Food and Drug Administration (USFDA) is for Leuprolide Acetate injection of strengths 14 mg/2.8 ml (1 mg/0.2…